Keywords: Andromeda Biotech, Clal Biotech, Teva, DiaPep277, Type 1 diabetes

Andromeda’s type 1 diabetes candidate DiaPep277 meets Ph III primary endpoint

Article | 22 November 2011

Print This

Israel-based Andromeda Biotech, a subsidiary of Clal Biotechnology Industries (TASE: CBI.TA), says initial results from a pivotal Phase III ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in